Weight-loss drugs are a hot commodity. But not in low-income neighborhoods.

Ozempic and other GLP-1 drugs were supposed to revolutionize the battle against obesity. But evidence shows big economic and racial disparities in access.

View original article
Contributor: Ariana Eunjung Cha